SGLT2 pill study for atrial fibrillation with type 2 diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 80 years old.
- You have had atrial fibrillation at least once in the past year, confirmed by an ECG.
- You have type 2 diabetes with HbA1c over 6.5%, and you take only pills (no insulin).
- When your heart rhythm is normal (sinus rhythm), your ECG measurements are within set limits.
- You must be able to sign informed consent and follow study steps.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
This trial tests if enavogliflozin, a diabetes drug, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people with heart failure. If you've recently had or are planning this procedure, this study may offer a new way to keep your heart rhythm steady.
This study tests whether a diabetes drug called an SGLT2 inhibitor can help keep your heart in a normal rhythm after a procedure to shock it back into rhythm. It is for people with persistent atrial fibrillation and a type of heart failure where the heart is stiff.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
This study tests whether a type of diabetes medication called an SGLT2 inhibitor can improve the structure and function of the heart's left atrium in people with type 2 diabetes. It may help prevent heart problems in the future.
This trial tests whether an SGLT2 inhibitor (a type of diabetes drug) can help prevent heart attacks, strokes, and other heart problems in people with high blood pressure. You may be eligible if you are 60 or older, have high blood pressure, and have had a heart or blood vessel event (like a heart attack or stroke) or have certain risk factors (like smoking, high cholesterol, or obesity).
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.